Hagerty, Inc. filings document the public-company record for a specialty vehicle insurance and automotive enthusiast business. Its reports include quarterly and annual results furnished on Form 8-K, Regulation FD materials, stockholder letters and disclosures about premium growth, policies in force, earned premium, profitability measures and insurance program economics.
Hagerty's filings also cover material agreements with Markel, including the completed fronting arrangement and related relationship and operating-company agreements. Proxy materials describe board composition, committee assignments, executive compensation, equity awards and shareholder voting matters, while other filings address Class A common stock registered on the New York Stock Exchange, secondary offering activity, insider and governance changes, and risk-related disclosure topics.
Hagerty (NYSE:HGTY) filed a Form 4 reporting routine insider activity by director Robert I. Kauffman.
- Between 06/25-06/27/2025, Kauffman, via Aldel LLC, sold 39,669 Class A shares at a weighted average price near $10.10.
- Sales were executed under a Rule 10b5-1 plan adopted 08/09/2024, signaling advance scheduling rather than opportunistic trading.
- Following the transactions, Kauffman retains 3,698,835 shares indirectly (Aldel LLC) and 67,302 shares directly.
The divestiture equals roughly 1 % of his total stake and $0.4 million in proceeds—levels considered non-material for Hagerty’s capitalization.
Director Robert I. Kauffman of Hagerty filed a Form 144 notice for the proposed sale of 7,432 shares of common stock with an aggregate market value of $75,212 through Merrill Lynch on the NYSE. The planned sale date is June 27, 2025.
The securities were originally acquired on December 2, 2021, as part of a PIPE financing connected to Hagerty's business combination. Kauffman's initial acquisition was 3.5 million shares.
Over the past three months (March-June 2025), Kauffman has conducted extensive trading activity through Aldel LLC, selling approximately 432,000 shares in multiple transactions, generating total proceeds of about $4.2 million. The trading has followed a 10b5-1 plan adopted on August 9, 2024.
The filing indicates Kauffman has no knowledge of material adverse information about Hagerty that hasn't been publicly disclosed. The company currently has 90,032,391 shares outstanding.